Drug Profile


Alternative Names: BILA 2011; BILA 2011BS

Latest Information Update: 30 Nov 2000

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antivirals; Branched-chain amino acids; Quinolines
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 30 Nov 2000 No-Development-Reported for HIV infections treatment in USA (PO)
  • 30 Nov 2000 No-Development-Reported for HIV infections treatment in Canada (PO)
  • 24 Sep 1997 A study has been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top